-
November 22, 2011
Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
-
October 31, 2011
Merck won't grow fast, but it's quality is undervalued. It's time for investors to reevaluate it.
-
February 18, 2011
Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
-
December 28, 2010
Big biotechs had a mixed year, with concerns about R&D costs and product sales. The stocks may have seen the worst ...
-
December 21, 2010
Possible European approval could save the day for this risky biotech.
-
October 29, 2010
While you never can be certain of what the future will bring, clearly Eli Lilly, Gilead Sciences, Biogen Idec all ...
-
September 23, 2010
Stocks trading below the S&P 500 P/E average are cheap, but are they a good buy?
-
September 10, 2010
Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
-
July 30, 2010
Sanofi is priced as though it will never grow again - that's usually a good sign of value.
-
July 29, 2010
Making bets on stocks that have been driven down too far can be a great way to catch some of the next batch of winners.
-
July 23, 2010
There's more to the story than one lousy quarter for PetMed Express and Gilead.
-
July 06, 2010
Gilead has carved out an exceptionally valuable niche, but should the company do more?
-
July 05, 2010
Here are some growth-oriented stocks with below-market average P/Es that investors can pick up during this shaky ...
-
June 22, 2010
Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
-
June 17, 2010
High-growth biotech stocks are now priced like value plays.
-
May 21, 2010
When Forest Labs' management realizes that its shares are cheap, the best use of the balance will be to buy back the ...
-
May 14, 2010
In booming markets, anyone can make money. In declining markets, not everyone can prevent significant capital loss. ...
-
May 13, 2010
Adaptive design is an idea whose time has come, and investors in biotechs and pharmaceuticals should stand to benefit.
-
May 10, 2010
Should investors hang on despite a devastating FDA decision?
-
April 27, 2010
Take a look inside the profit sharing and savings portfolio McDonald's runs for its employees.
